JDP Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Philadelphia PA United States (2008)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2011
NCT02024152
First Marketed Drug
2019
cetirizine (zyrtec)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

JDP Therapeutics, Inc. | JDP THERAPEUTICS INC

Active Ingredients

Marketed Drugs (1)

cetirizine (zyrtec) (2019)

Drugs in Phase 3 Trials (2)

cetirizine (zyrtec) (4 trials)

diphenhydramine (benadryl) (3 trials)

Drugs in Phase 2 Trials (1)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Urticaria (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3